[1] |
Ries L, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute, 2008[J]. 2007-11-01].
URL
|
[2] |
Pagani O, Goldhirsch A. Breast cancer in young women: Climbing for progress in care and knowledge[J]. J Clin Oncol, 2006, 2(5):717-732.
|
[3] |
Lhomme C, Pautier P, Zagame L, et al. Surveillance de l'endomètredes femmessous tamoxifène endometrial surveillance of women on tamoxifen[J]. Gynécol Obstét Fertil, 2003, 31(7-8):647-656.
|
[4] |
Group EBCTC. Tamoxifen for early breast cancer: An overview of the randomised trials[J]. Lancet, 1998, 351:1451-1467.
|
[5] |
Luo YF, Liu YH. Effect on endometrial by tamoxifen[J]. J Reprod Med, 2004, 13(6):338-341.
|
[6] |
Wang C, Wang C, Huang H, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. CA A Cancer J Clin, 2002, 94(8):2192-2198.
|
[7] |
Wen ZQ, Wang QX, Leng QG, et al. Clinical and pathological observations of oral norethisterone treatment of endometrial hyperplasia with menorrhagia[J].Progr Obstet Gynecol, 1999, 8(1):44-46.
|
[8] |
Rose P, Brandewie E, Abdul-Karim F. Failure of megestrol acetate to reverse tamoxifen induced endometrial neoplasia: Two case reports[J]. Int J Gynecol Cancer, 1999, 9(5):362-364.
|
[9] |
Montz F, Bristow R, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer[J]. Am J Obstet Gynecol, 2002, 186(4):651-657.
|
[10] |
Gardner F, Konje J, Abrams K, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: A randomised controlled trial[J]. Lancet, 2000, 356(9243):1711-1717.
|
[11] |
Chan S, Tam W, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG[J].Int J Obstet Gynaecol, 2007, 114(12):1510-1515.
|
[12] |
Gardner F, Konje J, Bell S, et al. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial[J]. Gynecol Oncol, 2009, 114(3):452-456.
|
[13] |
Chin J, Konje J, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen[J]. Cochrane Datab Syst Rev (Online), 2009, 4:20-23.
|
[14] |
Wang S, Zha XM. Effect of tamoxifen on uterus and ovaries of postmenopausal breast cancer patients[J].Acta Univ Med Nanjing, 2001, 21(4):320-321.
|
[15] |
Ji XQ, Sun GZ.Clinical analysis of ovarian cysts cause by tamoxifen treatment for breast cancer[J]. Clin Med China, 2003, 19(7):660-661.
|
[16] |
Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: Reproductive and late health effects of treatment[J]. J Clin Oncol, 2003, 21(22):4184-4193.
|
[17] |
Sun ZY, Shen K, Lang JH, et al. Effect on ovarian function in ovarian cancer patients after chemotherapy of preserve fertility function surgery[J]. Acta Acad Med Sin, 2003, 25(4):431-433.
|
[18] |
Kil WJ, Ahn SD, Shin SS, et al. Treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients. Breast cancer research and treatment[J].Breast Cancer Res Treat, 2006, 96(3):245-250.
|
[19] |
Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer[J]. Cancer Control, 2002, 9(6):466-472.
|
[20] |
Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy[J]. Cur Opin Obstet Gynecol, 2005, 17(1):21-26.
|
[21] |
Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a[J]. JNCI Monographs, 2005, 2005(34):40-43.
|
[22] |
Gwyn K. Children exposed to chemotherapy in utero[J]. JNCI Monographs, 2005, 2005(34):69-71.
|
[23] |
Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer[J]. Breast Cancer Res, 2007, 9(6):115.
|
[24] |
Pritchard KI. Endocrine therapy of advanced disease[J]. Clin Cancer Res, 2003, 9(1):460-467.
|
[25] |
Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: Trial stopped[J]. Lancet, 2004, 363(9407):453-455.
|
[26] |
von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: The Stockholm randomized trial[J]. J Nation Cancer Instit, 2005, 97(7):533-535.
|
[27] |
Sestak I, Kealy R, Edwards R, et al. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms[J]. J Clin Oncol, 2006, 24(24):3991-3996.
|
[28] |
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial[J]. JAMA: J Am Med Assoc, 2002, 288(3):321-333.
|
[29] |
Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J]. J Nation Cancer Instit, 2008, 100(7):475-482.
|
[30] |
Madalinska JB, van Beurden M, Bleiker E, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy[J]. J Clin Oncol, 2006, 24(22):3576-3582.
|
[31] |
Chiarelli AM, Kirsh VA, Klar NS, et al. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection[J]. Cancer Epidemiol Biomark Prevent, 2006, 15(10):1856-1862.
|
[32] |
Bordeleau L, Pritchard K, Goodwin P, et al. Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review[J]. Clin Therapeut, 2007, 29(2):230-241.
|
[33] |
Rapiti E, Fioretta G, Verkooijen HM, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001[J]. Eur J Cancer, 2005, 41(10):1446-1452.
|
[34] |
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer[J]. BMC cancer, 2006, 6(1):194.
|
[35] |
Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer[J]. J Clin Oncol, 2004, 22(20):4174-4183.
|
[36] |
Axelrod D, Smith J, Kornreich D, et al. Breast cancer in young women[J]. J Am College Surgeons, 2008, 206(6):1193-1203.
|
[37] |
Ives A, Saunders C, Bulsara M, et al. Pregnancy after breast cancer: Population based study[J]. BMJ, 2007, 334(7586):194.
|
[38] |
Blakely LJ, Buzdar AU, Lozada JA, et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence[J]. Cancer, 2004, 100(3):465-469.
|
[39] |
Avilés A, Neri N. Hematological malignancies and pregnancy: A final report of 84 children who received chemotherapy in utero[J]. Clin Lymphom, Myelom Leukem, 2001, 2(3):173-177.
|
[40] |
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5):283-291.
|
[41] |
Velentgas P, Daling JR, Malone KE, et al. Pregnancy after breast carcinoma[J]. Cancer, 1999, 85(11):2424-2432.
|
[42] |
Trinh XB, Tjalma WAA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients[J]. Fertil Steril, 2008, 90(1):17-22.
|
[43] |
Helewa MLP, Provencher D, Lea R, et al. Breast cancer, pregnancy, and breastfeeding[J]. J Obstet Gynaecol Canada, 2002, 24(2):164-180.
|
[44] |
Sacchini V, Pinotti JA, Barros ACSD, et al. Nipple-sparing mastectomy for breast cancer and risk reduction: Oncologic or technical problem[J]? J Am College Surgeons, 2006, 203(5):704-714.
|